Pharmacological Treatment of Patients with Alcohol Use Disorder
Publication Date: January 1, 2018
Last Updated: February 28, 2023
Guideline Statements
Assessment and Determination of Treatment Goals
APA recommends that the initial psychiatric evaluation of a patient with suspected alcohol use disorder include assessment of current and past use of tobacco and alcohol as well as any misuse of other substances, including prescribed or over-the-counter medications or supplements. (1, C)
307795
APA recommends that the initial psychiatric evaluation of a patient with suspected alcohol use disorder include a quantitative behavioral measure to detect the presence of alcohol misuse and assess its severity. (1, C)
307795
APA suggests that physiological biomarkers be used to identify persistently elevated levels of alcohol consumption as part of the initial evaluation of patients with alcohol use disorder or in the treatment of individuals who have an indication for ongoing monitoring of their alcohol use. (2, C)
307795
APA recommends that patients be assessed for co-occurring conditions (including substance use disorders, other psychiatric disorders, and other medical disorders) that may influence the selection of pharmacotherapy for alcohol use disorder. (1, C)
307795
APA suggests that the initial goals of treatment of alcohol use disorder (e.g., abstinence from alcohol use, reduction or moderation of alcohol use, other elements of harm reduction) be agreed on between the patient and clinician and that this agreement be documented in the medical record. (2, C)
307795
APA suggests that the initial goals of treatment of alcohol use disorder include discussion of the patient’s legal obligations (e.g., abstinence from alcohol use, monitoring of abstinence) and that this discussion be documented in the medical record. (2, C)
307795
APA suggests that the initial goals of treatment of alcohol use disorder include discussion of risks to self (e.g., physical health, occupational functioning, legal involvement) and others (e.g., impaired driving) from continued use of alcohol and that this discussion be documented in the medical record. (2, C)
307795
APA recommends that patients with alcohol use disorder have a documented comprehensive and person-centered treatment plan that includes evidence-based nonpharmacological and pharmacological treatments. (1, C)
307795
Selection of a Pharmacotherapy
APA recommends that naltrexone or acamprosate be offered to patients with moderate to severe alcohol use disorder who
- have a goal of reducing alcohol consumption or achieving abstinence
- prefer pharmacotherapy or have not responded to nonpharmacological treatments alone and
- have no contraindications to the use of these medications.
307795
APA suggests that disulfiram be offered to patients with moderate to severe alcohol use disorder who
- have a goal of achieving abstinence
- prefer disulfiram or are intolerant to or have not responded to naltrexone and acamprosate
- are capable of understanding the risks of alcohol consumption while taking disulfiram and
- have no contraindications to the use of this medication.
307795
APA suggests that topiramate or gabapentin be offered to patients with moderate to severe alcohol use disorder who
- have a goal of reducing alcohol consumption or achieving abstinence
- prefer topiramate or gabapentin or are intolerant to or have not responded to naltrexone and acamprosate and
- have no contraindications to the use of these medications.
307795
Recommendations Against Use of Specific Medications
APA recommends that antidepressant medications not be used for treatment of alcohol use disorder unless there is evidence of a co-occurring disorder for which an antidepressant is an indicated treatment. (1, B)
307795
APA recommends that in individuals with alcohol use disorder, benzodiazepines not be used unless treating acute alcohol withdrawal or unless a co-occurring disorder exists for which a benzodiazepine is an indicated treatment. (1, C)
307795
APA recommends that for pregnant or breastfeeding women with alcohol use disorder, pharmacological treatments not be used unless treating acute alcohol withdrawal with benzodiazepines or unless a co-occurring disorder exists that warrants pharmacological treatment. (1, C)
307795
APA recommends that acamprosate not be used by patients who have severe renal impairment. (1, C)
307795
APA recommends that for individuals with mild to moderate renal impairment, acamprosate not be used as a first-line treatment and, if used, the dose of acamprosate be reduced compared with recommended doses in individuals with normal renal function. (1, C)
307795
APA recommends that naltrexone not be used by patients who have acute hepatitis or hepatic failure. (1, C)
307795
APA recommends that naltrexone not be used as a treatment for alcohol use disorder by individuals who use opioids or who have an anticipated need for opioids. (1, C)
307795
Treatment of Alcohol Use Disorder and Co-occurring Opioid Use Disorder
APA recommends that in patients with alcohol use disorder and co-occurring opioid use disorder, naltrexone be prescribed to individuals who
- wish to abstain from opioid use and either abstain from or reduce alcohol use and
- are able to abstain from opioid use for a clinically appropriate time prior to naltrexone initiation.
307795
Recommendation Grading
Overview
Title
Pharmacological Treatment of Patients with Alcohol Use Disorder
Authoring Organization
American Psychiatric Association
Publication Month/Year
January 1, 2018
Last Updated Month/Year
July 24, 2024
Supplemental Implementation Tools
Document Type
Guideline
External Publication Status
Published
Country of Publication
US
Inclusion Criteria
Male, Female, Adult, Older adult
Health Care Settings
Ambulatory, Outpatient
Intended Users
Addiction treatment specialist, counselor, nurse, nurse practitioner, physician, physician assistant, psychologist
Scope
Assessment and screening, Treatment
Diseases/Conditions (MeSH)
D005235 - Fatty Liver, Alcoholic, D006519 - Hepatitis, Alcoholic, D000437 - Alcoholism
Keywords
alcohol use disorders, alcohol related disorders, drug dependence, alcoholism